Results 221 to 230 of about 179,215,740 (302)

A survey on the teaching of introductory nervous system content in undergraduate courses

Anatomical Sciences Education, EarlyView.
Abstract Teaching introductory or foundation level concepts about anatomy and physiology of the nervous system to undergraduate students presents a conundrum for educators—how to provide students with sufficient knowledge for a successful learning experience and outcome without overwhelming students and impacting student progression and retention.
Gabrielle Todd, Revecca Kakavanos‐Plew, Kay L. Double   +2 more
wiley   +1 more source

Between Guidelines and Daily Practice: The Persistent Use of Parenteral Depot Corticosteroids in Germany. [PDF]

Clin Transl Allergy
Taube C, Greulich T, Böing S, Pfaar O, Wagenmann M, Becker S, Sulk M, Gerkau NJ, Schwitalla JC, Vierbuchen T.   +9 more
europepmc   +1 more source

Age‐related differences in hydroxychloroquine‐associated adverse events: A pharmacovigilance study based on the FDA Adverse Event Reporting System

British Journal of Clinical Pharmacology, EarlyView.
Aims This real‐world pharmacovigilance study utilizes FDA Adverse Event Reporting System (FAERS) data (2004–2024) to characterize age‐related disparities in hydroxychloroquine (HCQ)‐associated adverse events (AEs), addressing gaps in age‐stratified risk assessment. Methods Disproportionality analysis (reporting odds ratios, RORs) and parametric Weibull
Guanghan Sun, Jingrong Yang, Lei Wan, Xia Xu, Jing Wang   +4 more
wiley   +1 more source

Characteristics of dermal fibroblasts and their biotherapeutic value in musculoskeletal system diseases. [PDF]

Front Bioeng Biotechnol
Zhou L, Zhang Q, Yang H, Zhang G, Fan M, Jin R, Zhou S.   +6 more
europepmc   +1 more source

Exposure‐adjusted safety and efficacy of GLP‐I and GLP‐1/GIP receptor agonists compared with non‐GLP‐I for weight management and type 2 diabetes: Based on FDA medical and statistical reports of 34 280 safety and 36 312 efficacy subjects

British Journal of Clinical Pharmacology, EarlyView.
Aims This work aimed to contextualize glucagon‐like peptide‐1 receptor agonists (GLP‐1 RAs) and glucose‐dependent insulinotropic polypeptide (GIP) receptor agonists safety and efficacy regarding weight management (WM); we analysed Food and Drug Administration (FDA) Medical Reviews to analyse 14 medications using patient‐exposure year normalization and ...
Aishwarya Prasad, Anshu Arora, Arun Arora, Jeena Vaid, Arif Khan   +4 more
wiley   +1 more source

Environmental Micro-Nanoplastics and Musculoskeletal Disorders: Current Research and Insights. [PDF]

Int J Nanomedicine
Ju C, Dong H, Liu R, Ma Y, Luo R, Hu H.
europepmc   +1 more source

Repeated intradermal lipopolysaccharide challenge responses in healthy volunteers: Implications for clinical pharmacology studies

British Journal of Clinical Pharmacology, EarlyView.
Aim Intradermal application of lipopolysaccharide (LPS), a Toll‐like receptor 4 agonist, induces a local inflammatory response and is used as a human challenge model to evaluate the pharmacodynamics of investigational medicinal products. While currently applied in a single, parallel‐group setting, alternative within‐subject designs involving repeated ...
Alexandra A. J. Sillé, Juliette A. van den Noort, Iva Lelios, Diana R. Pereira, Marzia A. Scelsi, Erica S. Klaassen, Philipp Schoenenberger, Naomi B. Klarenbeek, Pierre‐Eric Juif, Pascal Espie, Manon A. A. Jansen, Matthijs Moerland, Richard W. D. Welford   +12 more
wiley   +1 more source

The Health Benefits of Exercise: Molecular and Cellular Mechanisms. [PDF]

MedComm (2020)
Ying P, Wang H, Lu X, Zhang W, Lin Z, Wang K, Li S, Chen L, Jiang M, Hamad S, Wang Y, Wu J, Ling S.   +12 more
europepmc   +1 more source

Evaluating the (comparative) safety profile of the novel oral polio vaccine type 2 using individual case safety reports in VigiBase

British Journal of Clinical Pharmacology, EarlyView.
Aim Novel oral polio vaccine type 2 (nOPV2) was used under the WHO emergency use listing for circulating vaccine‐derived polio virus (cVDPV) outbreaks from 2021 to 2023. We assessed nOPV2 adverse events following immunization (AEFIs) and compared its safety profile to other vaccines using VigiBase.
Comfort Kunak Ogar, Malede Mequanent Sisay, Leonardo Roque‐Pereira, Christine Leopold, Patrick C. Souverein, Aukje K. Mantel‐Teeuwisse, Marie L. De Bruin   +6 more
wiley   +1 more source

Emerging mechanisms and translational advances in musculoskeletal diseases. [PDF]

J Orthop Translat
Xia T, Li B.
europepmc   +1 more source